PRESENTATION

Q3 2021 — Earnings presentation

Q3 2021PDF · 27 pages2.3 MB
Delivering a Smoke-Free Future
2021 Third-Quarter Results
October 19, 2021
Introduction
• A glossary of key terms and definitions, including the definition for reduced-risk products, or
"RRPs," additional heated tobacco unit market data, as well as adjustments, other calculations and
reconciliations to the most directly comparable U.S. GAAP measures are at the end of today’s
webcast slides, which are posted on our website
• Unless otherwise stated, all references to IQOS are to our IQOS heat-not-burn products. All
references to smoke-free products refer to RRPs
• Growth rates presented on an organic basis reflect currency-neutral underlying results
• Following the acquisitions of Fertin Pharma, OtiTopic, and Vectura Group, PMI added the "Other"
category in the third quarter of 2021. Business operations for the Other category are evaluated
separately from the geographical operating segments
2

-- 1 of 27 --

Forward-Looking and Cautionary Statements
• This presentation and related discussion contains projections of future results and other forward-looking statements. Achievement of future results is subject to risks,
uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary
materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is
identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking
statements made by PMI
• PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness,
eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and
other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the
effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; changes in adult smoker behavior; lost revenues as
a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and
limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other
agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its
data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize reduced-risk products
or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter
new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the
development of strategic business relationships; or if it is unable to attract and retain the best global talent. Future results are also subject to the lower predictability of our
reduced-risk product category's performance
• In addition, PMI’s business risks also include risks and uncertainties related to PMI’s acquisitions of Fertin Pharma A/S (“Fertin”), OtiTopic, Inc. ("OtiTopic") and Vectura
Group plc (“Vectura”), including, amongst other things: (1) the possibility that the integration of the operations of Fertin and Vectura with those of PMI may be more difficult
and/or take longer than anticipated, and may not accelerate PMI’s desired entry into additional smoke-free and beyond nicotine platforms as quickly as anticipated; (2) the
possibility that the respective integrations of Fertin and Vectura into PMI may be more costly than anticipated and may have unanticipated adverse results relating to
Fertin, Vectura or PMI’s existing businesses; (3) the inability to gain access to or acquire differentiated proprietary assets, technology and/or pharmaceutical development
expertise as anticipated by these acquisitions; (4) risks associated with third-party contracts containing consent and/or other contractual provisions that may be triggered
by the acquisitions; (5) the success of the research and development efforts of Fertin, OtiTopic and Vectura, including the ability to obtain regulatory approval for new
products, and the ability to commercialize or license these new products; (6) any unanticipated safety, quality or efficacy concerns and the impact of identified concerns
associated with the products developed by Fertin, OtiTopic and Vectura; and (7) the ability of PMI to retain key personnel of Fertin and Vectura, or hire key talent to work in
the Fertin and Vectura businesses due to their affiliation with PMI
• PMI is further subject to other risks detailed from time to time in its publicly filed documents, including the Form 10-Q for the quarter ended June 30, 2021. PMI cautions
that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking
statement that we may make from time to time, except in the normal course of its public disclosure obligations
3
Forward-Looking and Cautionary Statements (COVID-19)
• The COVID-19 pandemic has created significant societal and economic disruption, and resulted in closures of stores,
factories and offices, and restrictions on manufacturing, distribution and travel, all of which will adversely impact our
business, results of operations, cash flows and financial position during the continuation of the pandemic. Our business
continuity plans and other safeguards may not be effective to mitigate the impact of the pandemic
• Currently, significant risks include our diminished ability to convert adult smokers to our reduced-risk products, significant
volume declines in our duty-free business and certain other key markets, disruptions or delays in our manufacturing and
supply chain, increased currency volatility, and delays in certain cost saving, transformation and restructuring initiatives. Our
business could also be adversely impacted if key personnel or a significant number of employees or business partners become
unavailable due to the continuation of the COVID-19 pandemic. The significant adverse impact of COVID-19 on the
economic or political conditions in markets in which we operate could result in changes to the preferences of our adult
consumers and lower demand for our products, particularly for our mid-price or premium-price brands. Continuation of the
pandemic could disrupt our access to the credit markets or increase our borrowing costs. Governments may temporarily be
unable to focus on the development of science-based regulatory frameworks for the development and commercialization of
reduced-risk products or on the enforcement or implementation of regulations that are significant to our business. In
addition, messaging about the potential negative impacts of the use of our products on COVID-19 risks may lead to
increasingly restrictive regulatory measures on the sale and use of our products, negatively impact demand for our products,
the willingness of adult consumers to switch to our reduced-risk products and our efforts to advocate for the development of
science-based regulatory frameworks for the development and commercialization of reduced-risk products
• The impact of these risks also depends on factors beyond our knowledge or control, including the duration and severity of the
pandemic, its recurrence in our key markets, actions taken to contain its spread and to mitigate its public health effects, and
the ultimate economic consequences thereof
4

-- 2 of 27 --

Strong Q3 Performance Supports Full-Year Outlook
5
• Record high quarterly adjusted diluted EPS
• Excellent Q3, 2021 growth from IQOS despite device
supply constraints:
⎼ 33% RRP net revenue growth to reach 29% of total PMI
⎼ 24% broad-based HTU shipment volume growth
• Improving market share in combustibles, expect total
cigarette and HTU volume growth for the year
• IQOS ILUMA strong start in Japan
• Milestone acquisitions to support ambitions beyond
tobacco and nicotine
• Launch of Business Transformation-Linked Financing
Framework
• Returning cash to shareholders through increased
dividend and share repurchases
Source: PMI Financials or estimates
(a) Reflects total adjusted PMI net revenues divided by total PMI cigarette and HTU shipment volume
Source: PMI Financials or estimates 	6
Q3, 2021: Excellent Revenue and EPS Growth
(Organic variance vs. PY)
Net Revenues
Adjusted Diluted EPS
OI Margin
Net Revenue per Unit(a)
+8.5 %
(10) bps
+5.4 %
+7.6 %

-- 3 of 27 --

(a) Reflects total adjusted PMI net revenues divided by total PMI cigarette and HTU shipment volume
Source: PMI Financials or estimates 	7
YTD September, 2021: Strong Organic Growth
(Organic variance vs. PY)
Net Revenues
Adjusted Diluted EPS
OI Margin
Net Revenue per Unit(a)
+15.8 %
+280 bps
+5.7 %
+7.3 %
(a) On an organic basis
Source: PMI Financials or estimates
Reaffirming Strong Full-Year Outlook
• Revising organic growth assumption for net
revenues to upper half of previous range, with
strong margin expansion
• Narrowing adjusted diluted EPS forecast to
$6.01-6.06: representing 13-14% currency-
neutral growth, upper half of previous range:
⎼ Includes favorable currency impact of ~17 cents at
prevailing exchange rates
• Ongoing tightness in IQOS device supply; expect
HTU shipments of around 95 billion units
• EPS guidance does not include any material
impact from share repurchases or acquisitions:
⎼ Approx. $170m of share repurchases through
October 15
8
FY21 Outlook(a)
Adj. Net Revenue
Growth 6.5-7.0%
Adjusted OI
Margin Expansion ~200bps
Adjusted Diluted
EPS Growth 13-14%
HTU Shipment
Volume ~95 billion

-- 4 of 27 --

Continued Positive Regulatory Developments Recognizing
Harm Reduction Potential of RRPs
• Switzerland: On October 1st, the Swiss Parliament adopted a new Federal Law on Tobacco
Products and e-cigarettes, foreseen to enter into force by Q1 2023:
⎼ Dedicated product categories for non-combustible products such as HTPs, e-cigarettes and oral tobacco/snus
⎼ Non-combustible products have textual smokeless Health Warnings versus graphic health warnings for
cigarettes
• New Zealand: August publication of regulations for smoke free products, following the passage of
the Smoke-Free Environment (Vaping) Act 2020:
⎼ Recognizing that heated tobacco products are smokeless and have the potential to reduce harm, branded
packaging for HTPs can now be re-introduced with a 30% text warning specific for non-combustible products
• Egypt: Smoke-free products clearly differentiated from combustible cigarettes in both fiscal and
regulatory treatment
9
We continue to support regulatory and fiscal frameworks which recognize the substantial
risk reduction potential of non-combusted alternatives compared with combusted tobacco
Note: Sum does not foot due to rounding
Source: PMI Financials or estimates 10
Strong HTU Performance Driving Total Volume Growth
Total PMI Shipment Volume (billion units)
165.5 	164.8
19.0 	23.5
184.4 	188.3
Q3, 2020 	Q3, 2021
HTUs
Cigarettes
Total
23.8%
(0.4)%
2.1%
Change
vs. PY
473.8 	466.5
54.4 	69.6
528.2 	536.1
YTD Sept, 2020 	YTD Sept, 2021
HTUs
Cigarettes
Total
27.9%
(1.6)%
1.5%
Change
vs. PY
YTD	Q3

-- 5 of 27 --

HTU Volume Contribution Continues to Grow
(as a % of PMI Total Shipment Volume)
11
Note: Total volume includes HTUs and cigarettes
Source: PMI Financials or estimates
0.0% 0.9%
4.5% 5.3%
7.8%
10.8%
13.0%
2015 	2016 	2017 	2018 	2019 	2020 	YTD Sept, 2021
PMI HTU Shipment Volume (billion units)
7.4 	59.7	41.4	36.2	0.4 	76.1 	69.6
YTD Sept,
2020
YTD Sept,
2021
Source: PMI Financials or estimates 	12
Almost 30% of Revenues from Smoke-Free Products
(Smoke-Free Products as a % of Total PMI Adjusted Net Revenues)
0.2% 2.7%
12.7% 	13.8%
18.7%
23.8%
2015 	2016 	2017 	2018 	2019 	2020
$0.7 	$4.1	$3.6	$0.1 	$5.6
RRP Net Revenues ($ in billions)
$6.8 	$6.7
23.0%
28.6%
$4.9
2023 	2025
~40%
>50%
Ambition	Target

-- 6 of 27 --

13	Source: PMI Financials or estimates
Twin Engines Powering Organic Net Revenue Growth
+2.4pp
+3.1pp
+3.5pp
YTD Sept, 2021
Shipment
Volume
Increase
Organic Net
Revenue
Growth
YTD Sept, 2021
Adjusted Net
Revenue
Growth
+10.8%
Category & Market
Mix / Other
HTU and Device Pricing
Combustible Pricing
+7.3%
+0.3pp
Currency
+1.5%
14	Source: PMI Financials or estimates
Multiple Levers Driving OI Margin Expansion
+2.4pp
YTD Sept, 2020 	YTD Sept, 2021
(excluding currency)
YTD Sept, 2021
SG&A
Efficiencies
Gross Margin
Expansion
+44.4%
Currency
+41.6%
+44.6%
Adjusted OI Margin
+0.4pp 	+0.2pp

-- 7 of 27 --

Positive Market Share Momentum
15
Note: Excluding China and the U.S. Chart not to scale. Sum does not foot due to rounding
Source: PMI Financials or estimates
PMI Total International Share (in %)
24.7
23.2 23.7 24.4
3.0
3.5 3.5
3.6
27.7
26.6 27.3
28.0
FY 	Q1 	Q2 	Q3
2020 	2021
HTUs
Cigarettes
Total
20
Improving Combustible Trends
• Market recovery in Indonesia, Turkey,
Mexico
• Close to stable total industry volumes in EU
Region, modest decline in Russia
• Sequential growth in overall combustible
share
• Sequentially improved industry in the
Philippines and higher PMI share in South &
Southeast Asia despite renewed pandemic-
linked restrictions
16
Note: Excluding China and the U.S. Reflects sales volume of PMI cigarettes as a percentage of cigarette industry sales volume
Source: PMI Financials or estimates
25.7
24.2
24.8
25.6
FY 	Q1 	Q2 	Q3
Share of Cigarette Market (in %)
2021	2020
+1.4pp

-- 8 of 27 --

Impact of Device Supply Constraints
• Global semiconductor shortage impact on assortment & availability of IQOS devices in Q3:
⎼ Restrained commercial programs
⎼ Hampers ability to compete in certain markets
• Tight supply situation likely to persist into H1, 2022, impacting user growth:
⎼ Prioritizing necessary device replacements for existing users, followed by devices for acquisition
• Additional major ILUMA launches now assumed for H2, 2022
• Expect to re-accelerate growth when shortages ease:
⎼ IQOS ILUMA, further device and consumable innovations, new market entries, commercial investments to
drive growth
• If shortages persist, this could result in 2022 organic growth below our targeted 2021-23 average
rates for net revenues, OI margin expansion, EPS
• Confirm 2021-23 organic growth targets: Net Revenue >5% CAGR, OI margin ≥150bps annual
average increase and adjusted diluted EPS >9% CAGR
17	Source: PMI Financials or estimates
Total IQOS Users(a)
20.1
19.1
17.6
16.4
15.3
14.3
13.5
12.2
Estimated users who have switched to IQOS
and stopped smoking(a)
Estimated users who are in various stages of
conversion(a)
20.4
Q1
2019
Q3 	Q4 	Q2
2020
Q3 	Q4 	Q1 	Q2 	Q3
2021
18
(a) See Glossary for definition
Source: PMI Financials or estimates, IQOS user panels and PMI Market Research
+0.4
Excl. Belarus
IQOS User Growth Continues Despite Device Constraints
71% 	71% 	73% 	72% 	71% 	73% 	74% 	73% 	73%

-- 9 of 27 --

EU Region: Strong Underlying HEETS Growth
(a) Excluding the estimated impact of trade inventory movements
Note: Market share for HTUs is defined as the total sales volume for HTUs as a percentage of the total
estimated sales volume for cigarettes and HTUs
Source: PMI Financials or estimates
Adj. IMS (a)
(in billion units)
3.9% 	3.9% 	3.9%
5.0%
5.5% 5.3%
Q1 	Q2 	Q3 	Q4 	Q1 	Q2 	Q3
HTU SoM
2020 	2021
5.6%
19
4.1 4.5
5.2
5.7 6.0
6.7 7.1
Russia & Eastern Europe: Continued Robust PMI HTU Growth
(a) Excluding the estimated impact of trade inventory movements
Note: Market share for HTUs is defined as the total sales volume for
HTUs as a percentage of the total estimated sales volume for
cigarettes and HTUs
Source: PMI Financials or estimates
Russia
Adj. IMS (a)
(in billion units)
EE Region
Adj. IMS (a)
(in billion units)
4.4 	4.7 5.2 5.8 	6.1 6.5 	6.3
Russia HTU SoM	2.9 3.2 3.4
3.8 	3.9 	4.0 	4.0
6.5%
6.0% 5.8%
7.2%
7.7% 7.3%
6.9%
Q1 	Q2 	Q3 	Q4 	Q1 	Q2 	Q3
2020 	2021 	20

-- 10 of 27 --

6.7
7.1
7.6 	7.6 7.4
7.9
8.2
Japan: Continued IQOS HTU and Category Growth
(a) Adjusted market share for HTUs is defined as the total sales volume for HTUs as a percentage of the total estimated sales
volume for cigarettes, HTUs and cigarillos and excluding the impact of estimated trade inventory movements
(b) Excluding the impact of estimated trade inventory movements
Source: PMI Financials or estimates
Q1 	Q2 	Q3 	Q4 	Q1 	Q2 	Q3
18.7% 	18.8%
20.1%
20.8% 	21.0%
17.8%
2020 	2021
Adjusted Total Tobacco SoM(a)
Adj. IMS (b)
(in billion units)
20.8%
21
(a) Status at September 30, 2021
Note: Reflects markets where PMI smoke-free products are available in key cities or nationwide. Includes e-vapor launch in Finland and AG Snus products in Norway and Iceland. Reflects
date of initial geographic expansion beyond pilot launch city. The number of markets includes International Duty Free. Following recent international sanctions, IQOS is no longer available
for sale in Belarus. Low & Middle-Income markets defined using World Bank classification where available. Palestine is included as a Low & Middle-Income market
On Track to Reach 100 Markets by 2025
22
Market
Launches
2019 (7)
2015 (7)
2016 (13)
2017 (18)
2018 (6)
2020 (12)
Current:
70
Markets
Worldwide(a)
Of which:
28
Low & Middle-
Income Markets
2021 (7)
Target:
100
Markets in 5
years

-- 11 of 27 --

Confident in IQOS Strong Intellectual Property
• Clear leading innovator in the category with billions of dollars invested
• Strong IP portfolio on all IQOS smoke-free products
• Universal success in defending our products against IP challenges outside the U.S.:
⎼ 11 favorable rulings, including UK High Court and European Patent Office
• Presidential Review Period should consider public health impact for U.S. IQOS users
and FDA's assessment that IQOS is appropriate for the promotion of public health
• In scenario where Presidential Review upholds ITC decision:
⎼ Immaterial financial impact given early stage of U.S. IQOS rollout
⎼ Contingency plans underway including domestic production
• Continue to see large opportunity for IQOS in the U.S.
23
Outstanding Start for IQOS ILUMA in Japan
• Device sales well ahead of all comparable
past launches
• Growing proportion of new users
• TEREA HTU purchases growing rapidly to
reach over 10% of weekly offtake
• Improving NPS scores, very positive
consumer feedback
• Plan to launch in Switzerland in November
24

-- 12 of 27 --

IQOS VEEV Encouraging Early Results
• Strong progress following distribution and
consumable range expansions:
⎼ Italy: 7% estimated national exit volume offtake
share of closed system pods
⎼ Czech: 8% estimated national exit volume
offtake share of closed system pods
• Launched in Croatia in Q3, Canada in
October, with Ukraine planned later in Q4
• Preparations ongoing for U.S. PMTA
application in H2, 2022
25	Source: PMI Financials or estimates
Investing in Future Capabilities
26
	Note: CDMO stands for Contract Development and Manufacturing Organization
• Oral Hygiene
• Gastro-Intestinal
• Immune
Reduced-Risk Products 	Healthcare and Wellness
Selfcare Wellness
• Innovative oral and
inhalation drug delivery
formulations
• Focus on energy, sleep,
calm and focus
Inhaled Therapeutics
• Reformulated Rx drugs
• New Molecular Entities
(with partners)
Inhalable Products
• Heated Tobacco Products
• Vapor Products
Oral Products
• Nicotine pouches
• New modern oral forms of
nicotine delivery
• Oral and intraoral formulation
• Inhalable device & formulation
• Dry powder
inhalation
+
CDMO
Business
• Continue
to grow

-- 13 of 27 --

ACCESS TO SMOKE-FREE PRODUCTS
• 	Continue to broaden access to smoke-free products, increasing availability with
new product launches across a growing range of markets
NEW BUSINESS AREAS BEYOND TOBACCO AND NICOTINE
• 	Recent investments bolster smoke-free objectives and mark a milestone in
seeking a net positive impact
BUSINESS TRANSFORMATION-LINKED FINANCING FRAMEWORK
• Refinancing with Revolving Credit Facility under the framework
• Linking financing to material sustainability targets
• Following ICMA principles, with Second Party Opinion from S&P
ENVIRONMENTAL IMPACT
• 	On track to achieve Scope 1 & 2 carbon neutrality by 2025, 5 years ahead of target
• 	With upcoming United Nations Climate Change Conference (COP26); PMI will
publish:
⎼ 	Low Carbon Transition Plan
⎼ 	White paper on Climate Justice (highlighting connectivity between
Environmental & Social issues)
Transforming for a Sustainable Future
27
	Note: ICMA stands for International Capital Market Association
28
On Track for Strong 2021 Performance
• 	Record quarterly EPS; on track for excellent top and
bottom-line growth in 2021
• 	Strong underlying momentum for IQOS
• 	Broadening smoke-free portfolio & geographic reach
• 	Investing for long-term growth beyond nicotine
• 	Increasing cash returns to shareholders
• 	More exciting innovations in 2022; IQOS user
growth to re-accelerate when device shortages ease
• 	Confident in 2021-23 growth algorithm

-- 14 of 27 --

Delivering a Smoke-Free Future
2021 Third-Quarter Results
Questions & Answers
iOS Download 	Android Download	Have you downloaded the new PMI Investor Relations App yet?
The free IR App is available to download at the Apple App Store
for iOS devices and at Google Play for Android mobile devices
Or go to: www.pmi.com/irapp
Delivering a Smoke-Free Future
2021 Third-Quarter Results
October 19, 2021

-- 15 of 27 --

31
Glossary of Key Terms and Definitions,
Appendix, and
Reconciliation of Non-GAAP Measures
Glossary: General Terms
• "PMI" refers to Philip Morris International Inc. and its subsidiaries. Trademarks and service marks that are the registered property of, or
licensed by, the subsidiaries of PMI, are italicized
• Until March 28, 2008, PMI was a wholly owned subsidiary of Altria Group, Inc. ("Altria"). Since that time the company has been independent and
is listed on the New York Stock Exchange (ticker symbol "PM")
• Comparisons are made to the same prior-year period unless otherwise stated
• Unless otherwise stated, references to total industry, total market, PMI shipment volume and PMI market share performance reflect cigarettes
and heated tobacco units
• References to total international market, defined as worldwide cigarette and heated tobacco unit volume excluding the U.S., total industry, total
market and market shares are PMI estimates for tax-paid products based on the latest available data from a number of internal and external
sources and may, in defined instances, exclude the People's Republic of China and/or PMI's duty free business
• 2020 and 2021 estimates for total industry volume and market share in certain geographies reflect limitations on the availability and accuracy
of industry data during pandemic-related restrictions
• "OTP" is defined as "other tobacco products," primarily roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and cigarillos, and
does not include reduced-risk products
• "Combustible products" is the term PMI uses to refer to cigarettes and OTP, combined
• In-market sales, or "IMS," is defined as sales to the retail channel, depending on the market and distribution model
• "Total shipment volume" is defined as the combined total of cigarette shipment volume and heated tobacco unit shipment volume
• Following the acquisitions of Fertin Pharma A/S, OtiTopic, Inc. and Vectura Group plc., PMI added the "Other" category in the third quarter of
2021. Business operations for the Other category are evaluated separately from the geographical operating segments
• "RBH" refers to PMI’s Canadian subsidiary, Rothmans, Benson & Hedges Inc.
• The Companies’ Creditors Arrangement Act (CCAA) is a Canadian federal law that permits a Canadian business to restructure its affairs while
carrying on its business in the ordinary course
32

-- 16 of 27 --

Glossary: General Terms (cont.)
• "EU" is defined as the European Union Region
• "EE" is defined as the Eastern Europe Region
• "ME&A" is defined as the Middle East & Africa Region and includes PMI's duty free business
• "S&SA" is defined as the South & Southeast Asia Region
• "EA&A" is defined as the East Asia & Australia Region
• “AMCS” is defined as the Americas Region. It refers to the former Latin America & Canada segment, which was renamed as the Americas
segment as of the third quarter of 2021.
• Following the deconsolidation of PMI's Canadian subsidiary, Rothmans, Benson & Hedges, Inc. (RBH), PMI will continue to report the volume of
brands sold by RBH for which other PMI subsidiaries are the trademark owner. These include HEETS, Next, Philip Morris and Rooftop
• From time to time, PMI’s shipment volumes are subject to the impact of distributor inventory movements, and estimated total industry/market
volumes are subject to the impact of inventory movements in various trade channels that include estimated trade inventory movements of
PMI’s competitors arising from market-specific factors that significantly distort reported volume disclosures. Such factors may include changes
to the manufacturing supply chain, shipment methods, consumer demand, timing of excise tax increases or other influences that may affect the
timing of sales to customers. In such instances, in addition to reviewing PMI shipment volumes and certain estimated total industry/market
volumes on a reported basis, management reviews these measures on an adjusted basis that excludes the impact of distributor and/or estimated
trade inventory movements. Management also believes that disclosing PMI shipment volumes and estimated total industry/market volumes in
such circumstances on a basis that excludes the impact of distributor and/or estimated trade inventory movements, such as on an IMS basis,
improves the comparability of performance and trends for these measures over different reporting periods
• "ESG" stands for environmental, social, and governance
• "Illicit trade" refers to domestic non-tax paid products
• "OECD" is defined as Organisation for Economic Co-operation and Development
• "SoM" stands for share of market
33
Glossary: Financial Terms
• Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping
and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. PMI recognizes revenue when control is
transferred to the customer, typically either upon shipment or delivery of goods
• Net revenues related to RRPs represent the sale of heated tobacco units, heat-not-burn devices and related accessories, and other nicotine-
containing products, primarily e-vapor and oral nicotine products, including shipping and handling charges billed to customers, net of sales
and promotion incentives, and excise taxes. PMI recognizes revenue when control is transferred to the customer, typically either upon
shipment or delivery of goods
• Adjusted net revenues exclude the impact related to the Saudi Arabia customs assessments
• "SG&A" stands for selling, general & administrative
• "Adjusted Operating Income (OI) Margin" is calculated as adjusted OI, divided by adjusted net revenues
• "Net debt" is defined as total debt, less cash and cash equivalents
• Growth rates presented on an organic basis for consolidated financial results reflect currency-neutral underlying results
• Management reviews net revenues, OI, OI margins, operating cash flow and earnings per share, or "EPS," on an adjusted basis, which may
exclude the impact of currency and other items such as acquisitions, asset impairment and exit costs, tax items and other special items.
Organic growth rates reflect the way management views underlying performance for these measures. PMI believes that such measures,
including pro forma measures, will provide useful insight into underlying business trends and results.
• "Fair value adjustment for equity security investments" reflects the adjustment resulting from share price movements in passive
investments for publicly traded entities that are not controlled or influenced by PMI. Under U.S. GAAP, such adjustments are required, since
January 1, 2018, to be reflected directly in the income statement
34

-- 17 of 27 --

Glossary: Reduced-Risk Products
• Reduced-risk products (“RRPs”) is the term PMI uses to refer to products that present, are likely to present, or have the potential to
present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of
development, scientific assessment and commercialization. PMI's RRPs are smoke-free products that contain and/or generate far lower
quantities of harmful and potentially harmful constituents than found in cigarette smoke
• "Aerosol" refers to a gaseous suspension of fine solid particles and/or liquid droplets
• "Combustion" is the process of burning a substance in oxygen, producing heat and often light
• "Smoke" is a visible suspension of solid particles, liquid droplets and gases in air, emitted when a material burns
• "Heated tobacco units," or "HTUs," is the term PMI uses to refer to heated tobacco consumables, which for PMI include the company's
HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro and HEETS FROM MARLBORO (defined collectively as HEETS), Marlboro
Dimensions, Marlboro HeatSticks, Parliament HeatSticks and Terea, as well as the KT&G-licensed brand, Fiit and Miix (outside of Korea)
• The IQOS heat-not-burn device is a precisely controlled heating device into which a specially designed and proprietary tobacco unit is
inserted and heated to generate an aerosol
• "PMI heat-not-burn products" include licensed KT&G heat-not-burn products
• "PMI HTUs" include licensed KT&G HTUs
• HTU "offtake volume" represents the estimated retail offtake of HTUs based on a selection of sales channels that vary by market, but
notably include retail points of sale and e-commerce platforms
• HTU "offtake share" represents the estimated retail offtake volume of HTUs divided by the sum of estimated total offtake volume for
cigarettes and HTUs
• Market share for HTUs is defined as the total sales volume for HTUs as a percentage of the total estimated sales volume for cigarettes and
HTUs
• "Total IQOS users" is defined as the estimated number of Legal Age (minimum 18 years) users of PMI heat-not-burn products for which
PMI HTUs represented at least 5% of their daily tobacco consumption over the past seven days. Note: as of December 2020, PMI heat-
not-burn products and HTUs include licensed KT&G heat-not-burn products and HTUs, respectively 	35
Glossary: Reduced-Risk Products (cont.)
• The estimated number of adults who have "switched to IQOS and stopped smoking" reflects:
⎼ for markets where there are no heat-not-burn products other than PMI heat-not-burn products: daily individual consumption of PMI HTUs represents
the totality of their daily tobacco consumption in the past seven days
⎼ for markets where PMI heat-not-burn products are among other heat-not-burn products: daily individual consumption of HTUs represents the totality
of their daily tobacco consumption in the past seven days, of which at least 70% is PMI HTUs.
Note: as of December 2020, PMI heat-not-burn products and HTUs include licensed KT&G heat-not-burn products and HTUs, respectively
• "FDA" stands for the U.S. Food & Drug Administration
• "MRTP" stands for Modified Risk Tobacco Product, the term used by the U.S. FDA to refer to RRPs
• "MRTP application" stands for Modified Risk Tobacco Product application under section 911 of the FD&C Act
• "PMTA" stands for Premarket Tobacco Application under section 910 of the FD&C Act
• "Acquisition" refers to our efforts to switch LAS from smoking cigarettes to RRPs or to switch LAU from competing smoke-free products to
PMI’s RRPs
• "Retention" refers to our efforts to deter LAU from going back to smoking cigarettes or from choosing a competing smoke-free product instead
of a PMI RRP
36

-- 18 of 27 --

Glossary: IQOS in the United States
• On April 30, 2019, the U.S. Food and Drug Administration (FDA) announced that the marketing of a version of PMI's Platform 1 product, namely, IQOS
2.4, together with its heated tobacco units (the term PMI uses to refer to heated tobacco consumables), is appropriate for the protection of public health
and authorized it for sale in the U.S. The FDA’s decision followed its comprehensive assessment of PMI’s premarket tobacco product applications
(PMTAs) submitted to the Agency in 2017
• In the third quarter of 2019, PMI brought IQOS 2.4 and three variants of its heated tobacco units to the U.S. through its license with Altria Group, Inc.,
whose subsidiary, Philip Morris USA Inc., is responsible for marketing the product and complying with the provisions set forth in the FDA's marketing
orders
• On July 7, 2020, the FDA authorized the marketing of a version of PMI's Platform 1 product, namely, IQOS 2.4, together with its heated tobacco units, as a
Modified Risk Tobacco Product (MRTP). In doing so, the agency found that an IQOS exposure modification order is appropriate to promote the public
health. The decision followed a review of the extensive scientific evidence package PMI submitted to the FDA in December 2016 to support its MRTP
applications
• On December 7, 2020, the FDA confirmed that the marketing of a version of PMI's Platform 1 product, namely, IQOS 3, is appropriate for the protection
of public health and authorized it for sale in the U.S. The FDA’s decision followed an assessment of a PMI's PMTA filed with the agency in March 2020
• Shipment volume of heated tobacco units to the U.S. is included in the heated tobacco unit shipment volume of the Americas segment. Revenues from
shipments of Platform 1 devices, heated tobacco units and accessories to Altria Group, Inc. for sale under license in the U.S. are included in Net Revenues
of the Americas
• In April 2020, affiliates of British American Tobacco plc (BAT) filed a complaint against PMI, Philip Morris Products S.A., Altria Group, Inc., and its
subsidiaries before the International Trade Commission (ITC). On May 14, 2021, the administrative law judge issued an Initial and Recommended
Determination (ID/RD) finding that the IQOS Platform 1 product commercialized in the U.S. infringes two of the three patents asserted by Plaintiffs,
recommending that the ITC issue a Limited Exclusion Order (LEO) against infringing products and recommending against a cease-and-desist order (CDO),
as well as recommending against a bond pending Presidential review of the ITC's Final Determination (FD). On September 29, 2021, the ITC issued its FD,
in which it upheld the finding of infringement in the ID and found a subsequent violation. The ITC issued a LEO prohibiting the importation of infringing
tobacco heating articles and components thereof and CDOs against Philip Morris USA, Inc. and Altria Client Services, LLC. The case is now in a 60-day
Presidential Review Period. PMI will appeal the patent and statutory issues at the appropriate time and has contingency plans underway, including
domestic production. Furthermore, BAT lawsuits based on the same patent families have repeatedly and universally failed in European courts and the
European Patent Office. The decision has no bearing outside the United States
37
38
2015 	2016 	2017 	2018 	2019 	2020
R&D expenditure
(smoke-free/total) 	70% 	72% 	74% 	92% 	98% 	99%
Commercial expenditure (Marketing)
(smoke-free/total) 	8% 	15% 	39% 	60% 	71% 	76%
Net revenues
(smoke-free/total) 	0.2% 	2.7% 	12.7% 	13.8% 	18.7% 	23.8%
Smoke-free product shipment ratio(a)
(smoke-free/total) 	0.1% 	0.9% 	4.4% 	5.1% 	7.6% 	10.4%
Estimated users who have stopped smoking and
switched to IQOS(b) (in millions) 	- 	1.5 	4.7 	6.6 	9.7 	12.7
Number of markets where net revenues from smoke-
free products exceed 50% of total net revenues 	- 	- 	1 	3 	4 	6
(a) The smoke-free product shipment ratio is computed based on millions of units. Smoke-free products include heated tobacco units and e-cigarettes. Total products include smoke-free
products, cigarettes and other combustible products
(b) See Glossary for definition
Source: PMI Financials or estimates, IQOS user panels and PMI Market Research
Business Transformation Metrics
Shifting Our Resources to Deliver a Smoke-Free Future

-- 19 of 27 --

Key Cities Provide Excellent Base for Growth
39
(a) Japan total market includes the cigarillo category
Note: Kuala L. is Kuala Lumpur
Source: PMI Financials or estimates
33.3% 25.5% 	23.6% 19.7% 	19.6% 	17.9% 	16.7% 	14.7% 	13.6%
Vilnius 	Tokyo 	Kiev 	Bratislava 	Athens 	Rome 	Prague 	Moscow 	Lisbon
13.2% 	13.0% 	12.9% 9.4% 	8.1% 	7.4% 	7.0% 	5.0% 	2.2%
Kuala L. 	Warsaw 	Milan 	Seoul 	Munich 	Zurich 	Bucharest 	London 	Madrid
+4.2pp 	+5.6pp 	+4.9pp 	+5.2pp 	+0.7pp 	+2.7pp
+1.7pp 	(0.2)pp 	+2.4pp 	+2.7pp 	+1.8pp 	+0.6pp
PMI HTU Offtake Shares (Q3, 2021)
+2.2pp
+0.3pp
Change vs. PY
(a)
+2.1pp 	+5.5pp
+1.8pp 	+4.1pp
EU Region: HEETS SoM Performance in Select Markets
Note: Select markets where HEETS share is ≥ 1%. Sales volume of PMI HTUs as a percentage of the total industry sales volume for cigarettes and HTUs
Source: PMI Financials or estimates 	40
Q3, 2021
Growth
vs. PY 	Q3, 2021
Growth
vs. PY 	Q3, 2021
Growth
vs. PY
Croatia 	5.7% 	+1.3pp 	Italy 	10.8% 	+3.0pp 	Romania 	3.4% 	+0.9pp
Czech
Republic 	9.9 	+1.9 	Latvia 	9.7 	(0.6) Slovak
Republic 	10.7 	+1.6
Germany 	2.8 	+0.9 	Lithuania 	22.3 	+2.3 	Slovenia 	7.2 	+2.8
Greece 	12.1 	+1.7 	Poland 	6.0 	+1.3 	Switzerland 	5.7 	+1.9
Hungary 	16.9 	+7.5 	Portugal 	11.5 	+2.6 	UK 	1.9 	+0.7

-- 20 of 27 --

Source: PMI Financials or estimates
2021: EPS Guidance
($/share)
41
Full-Year
≥
2021
Forecast 	2020
Organic
Growth
Reported Diluted EPS 	$5.77 – $5.82 	$5.16
- Saudi Arabia customs assessments 	0.14 	–
- Asset impairment and exit costs 	0.09 	0.08
- Asset acquisition cost 	0.03 	–
- Equity investee ownership dilution 	(0.02) 	–
- Fair value adjustment for equity security investments 	0.04
- Tax items 	(0.06)
- Brazil indirect tax credit 	(0.05)
Adjusted Diluted EPS 	$6.01 – $6.06 	$5.17
- Currency 	(0.17)
Adjusted Diluted EPS, excluding currency 	$5.84 – $5.89 	$5.17 	13% – 14%
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
42
Reconciliation of Reported Diluted EPS to Reported Diluted EPS, excluding Currency,
and Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS, excluding Currency
(Unaudited)
Quarters Ended September 30,
2021 	2020 	% Change
Reported Diluted EPS 	$ 1.55 	$ 1.48 	4.7%
Less: Currency 	0.04
Reported Diluted EPS, excluding Currency 	$ 1.51 	$ 1.48 	2.0%
Quarters Ended September 30, 	Year Ended
2021 	2020 	% Change 	2020
Reported Diluted EPS 	$ 1.55 	$ 1.48 	4.7% 	$ 5.16
Saudi Arabia customs assessments 	- 	- 	-
Asset impairment and exit costs 	0.02 	- 	0.08
Asset acquisition cost 	0.03 	- 	-
Equity investee ownership dilution 	(0.02) 	- 	-
Fair value adjustment for equity security investments 	- 	- 	0.04
Tax items 	- 	(0.06) 	(0.06)
Brazil indirect tax credit 	- 	- 	(0.05)
Adjusted Diluted EPS 	$ 1.58 	$ 1.42 	11.3% 	$ 5.17
Less: Currency 	0.04
Adjusted Diluted EPS, excluding Currency 	$ 1.54 	$ 1.42 	8.5%

-- 21 of 27 --

43
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Net Revenues by Product Category and Adjustments of Net Revenues for the Impact of Currency and Acquisitions
($ in millions) / (Unaudited)
Note: Sum of product categories or Regions might not foot to Total PMI due to roundings. “-“ indicates amounts between -$0.5 million and +$0.5 million
Currency
Net
Revenues
excluding
Currency
Acquisitions
Net
Revenues
excluding
Currency &
Acquisitions
Quarters Ended
September 30,
Net
Revenues 	Total 	Excluding
Currency
Excluding
Currency &
Acquisitions
2021 	Reduced-Risk Products 	2020 	% Change
$ 1,022 	$ 40 	$ 982 	$ 2 	$ 979 	European Union 	$ 706 	44.7% 	39.0% 	38.7%
306 	(6) 	313 	- 	313 	Eastern Europe 	263 	16.4% 	18.8% 	18.8%
44 	1 	44 	- 	44 	Middle East & Africa 	- 	- 	- 	-
4 	- 	4 	- 	4 	South & Southeast Asia 	- 	- 	- 	-
932 	(11) 	943 	- 	943 	East Asia & Australia 	753 	23.7% 	25.1% 	25.1%
18 	1 	18 	- 	18 	Americas 	7 	+100% 	+100% 	+100%
$ 2,326 	$ 24 	$ 2,302 	$ 2 	$ 2,300 	Total RRPs 	$ 1,730 	34.5% 	33.1% 	33.0%
2021 	PMI 	2020 	% Change
$ 3,192 	$ 128 	$ 3,064 	$ 2 	$ 3,062 	European Union 	$ 2,950 	8.2% 	3.9% 	3.8%
941 	(13) 	954 	- 	954 	Eastern Europe 	899 	4.7% 	6.1% 	6.1%
945 	(27) 	972 	- 	972 	Middle East & Africa 	768 	23.0% 	26.6% 	26.6%
1,065 	6 	1,059 	- 	1,059 	South & Southeast Asia 	1,071 	(0.6)% 	(1.1)% 	(1.1)%
1,523 	(7) 	1,530 	- 	1,530 	East Asia & Australia 	1,358 	12.2% 	12.7% 	12.7%
456 	20 	436 	- 	436 	Americas 	400 	14.0% 	9.0% 	9.0%
$ 8,122 	$ 107 	$ 8,015 	$ 2 	$ 8,013 	Total PMI 	$ 7,446 	9.1% 	7.6% 	7.6%
Net
Revenues
44
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Reconciliation of Net Revenues to Adjusted Net Revenues, excluding Currency and Acquisitions
($ in millions) / (Unaudited)
Net
Revenues
Adjusted
Net
Revenues
Currency
Adjusted
Net
Revenues
excluding
Currency
Acqui-
sitions
Adjusted
Net
Revenues
excluding
Currency
& Acqui-
sitions
Net
Revenues
Adjusted
Net
Revenues
Total 	Excluding
Currency
Excluding
Currency
& Acqui-
sitions
2021 	2020
$ 3,192 	$ - 	$ 3,192 	$ 128 	$ 3,064 	$ 2 	$ 3,062 	European Union 	$ 2,950 	$ - 	$ 2,950 	8.2% 	3.9% 	3.8%
941 	- 	941 	(13) 	954 	- 	954 	Eastern Europe 	899 	- 	899 	4.7% 	6.1% 	6.1%
945 	- 	945 	(27) 	972 	- 	972 	Middle East & Africa 	768 	- 	768 	23.0% 	26.6% 	26.6%
1,065 	- 	1,065 	6 	1,059 	- 	1,059 	South & Southeast Asia 	1,071 	- 	1,071 	(0.6)% 	(1.1)% 	(1.1)%
1,523 	- 	1,523 	(7) 	1,530 	- 	1,530 	East Asia & Australia 	1,358 	- 	1,358 	12.2% 	12.7% 	12.7%
456 	- 	456 	20 	436 	- 	436 	Americas 	400 	- 	400 	14.0% 	9.0% 	9.0%
$ 8,122 	$ - 	$ 8,122 	$ 107 	$ 8,015 	$ 2 	$ 8,013 	Total PMI 	$ 7,446 	$ - 	$ 7,446 	9.1% 	7.6% 	7.6%
Special
Items
Special
Items
Quarters Ended
September 30, 	% Change

-- 22 of 27 --

45
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Reconciliation of Operating Income to Adjusted Operating Income, excluding Currency and Acquisitions
($ in millions) / (Unaudited)
(a) Represents asset impairment and exit costs
(b) Represents asset acquisition cost related to OtiTopic Inc. in August 2021
Operating
Income
Adjusted
Operating
Income
Currency
Adjusted
Operating
Income
excluding
Currency
Acqui-
sitions
Adjusted
Operating
Income
excluding
Currency
& Acqui-
sitions
Operating
Income
Adjusted
Operating
Income
Total 	Excluding
Currency
Excluding
Currency
& Acqui-
sitions
2021 	2020
$ 1,680 	$ (12) (a)	
$ 1,692 	$ 79 	$ 1,613 	$ - 	$ 1,613 	European Union 	$ 1,588 	$ - 	$ 1,588 	6.5% 	1.6% 	1.6%
338 	(2) (a)	
340 	30 	310 	- 	310 	Eastern Europe 	245 	- 	245 	38.8% 	26.5% 	26.5%
388 	(3) (a)	
391 	(29) 	420 	- 	420 	Middle East & Africa 	261 	- 	261 	49.8% 	60.9% 	60.9%
348 	(4) (a)	
352 	4 	348 	- 	348 	South & Southeast Asia 	402 	- 	402 	(12.4)% 	(13.4)% 	(13.4)%
631 	(21) (a)	
652 	(23) 	675 	- 	675 	East Asia & Australia 	637 	- 	637 	2.4% 	6.0% 	6.0%
121 	(1) (a)	
122 	4 	118 	- 	118 	Americas 	110 	- 	110 	10.9% 	7.3% 	7.3%
(51) 	(51) (b)	
- 	- 	- 	- 	- 	Other 	- 	- 	- 	- 	- 	-
$ 3,455 	$ (94) 	$ 3,549 	$ 65 	$ 3,484 	$ - 	$ 3,484 	Total PMI 	$ 3,243 	$ - 	$ 3,243 	9.4% 	7.4% 	7.4%
Asset
Impairment
& Exit Costs
and Others
Asset
Impairment
& Exit Costs
Quarters Ended
September 30, 	% Change
46
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Reconciliation of Adjusted Operating Income Margin, excluding Currency and Acquisitions
($ in millions) / (Unaudited)
(a) For the calculation of Adjusted Operating Income and Adjusted Operating Income excluding currency and acquisitions refer to slide 45
(b) For the calculation of Adjusted Net Revenues excluding currency and acquisitions refer to slide 44
Adjusted
Operating
Income
(a)
Adjusted
Net
Revenues
(b)
Adjusted
Operating
Income
Margin
Adjusted
Operating
Income
excluding
Currency
(a)
Adjusted
Net
Revenues
excluding
Currency
(b)
Adjusted
Operating
Income
Margin
excluding
Currency
Adjusted
Operating
Income
excluding
Currency &
Acqui-
sitions (a)
Adjusted
Net
Revenues
excluding
Currency &
Acqui-
sitions (b)
Adjusted
Operating
Income
Margin
excluding
Currency &
Acqui-
sitions
Adjusted
Operating
Income
(a)
Adjusted
Net
Revenues
(b)
Adjusted
Operating
Income
Margin
Adjusted
Operating
Income
Margin
Adjusted
Operating
Income
Margin
excluding
Currency
Adjusted
Operating
Income
Margin
excluding
Currency &
Acqui-
sitions
2021 	2020 	% Points Change
$ 1,692 	$ 3,192 	53.0% 	$ 1,613 	$ 3,064 	52.6% 	$ 1,613 	$ 3,062 	52.7% 	European Union 	$ 1,588 	$ 2,950 	53.8% 	(0.8) 	(1.2) 	(1.1)
340 	941 	36.1% 	310 	954 	32.5% 	310 	954 	32.5% 	Eastern Europe 	245 	899 	27.3% 	8.8 	5.2 	5.2
391 	945 	41.4% 	420 	972 	43.2% 	420 	972 	43.2% 	Middle East & Africa 	261 	768 	34.0% 	7.4 	9.2 	9.2
352 	1,065 	33.1% 	348 	1,059 	32.9% 	348 	1,059 	32.9% South & Southeast Asia 	402 	1,071 	37.5% 	(4.4) 	(4.6) 	(4.6)
652 	1,523 	42.8% 	675 	1,530 	44.1% 	675 	1,530 	44.1% 	East Asia & Australia 	637 	1,358 	46.9% 	(4.1) 	(2.8) 	(2.8)
122 	456 	26.8% 	118 	436 	27.1% 	118 	436 	27.1% 	Americas 	110 	400 	27.5% 	(0.7) 	(0.4) 	(0.4)
$ 3,549 	$ 8,122 	43.7% 	$ 3,484 	$ 8,015 	43.5% 	$ 3,484 	$ 8,013 	43.5% 	Total PMI 	$ 3,243 	$ 7,446 	43.6% 	0.1 	(0.1) 	(0.1)
Quarters Ended
September 30,

-- 23 of 27 --

PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
47
Reconciliation of Reported Diluted EPS to Reported Diluted EPS, excluding Currency,
and Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS, excluding Currency
(Unaudited)
Nine Months Ended September 30,
2021 	2020 	% Change
Reported Diluted EPS 	$ 4.48 	$ 3.90 	14.9%
Less: Currency 	0.18
Reported Diluted EPS, excluding Currency 	$ 4.30 	$ 3.90 	10.3%
Nine Months Ended September 30, 	Year Ended
2021 	2020 	% Change 	2020
Reported Diluted EPS 	$ 4.48 	$ 3.90 	14.9% 	$ 5.16
Saudi Arabia customs assessments 	0.14 	- 	-
Asset impairment and exit costs 	0.09 	0.04 	0.08
Asset acquisition cost 	0.03 	- 	-
Equity investee ownership dilution 	(0.02) 	- 	-
Fair value adjustment for equity security investments 	- 	0.04 	0.04
Tax items 	- 	(0.06) 	(0.06)
Brazil indirect tax credit 	- 	- 	(0.05)
Adjusted Diluted EPS 	$ 4.72 	$ 3.92 	20.4% 	$ 5.17
Less: Currency 	0.18
Adjusted Diluted EPS, excluding Currency 	$ 4.54 	$ 3.92 	15.8%
48
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Net Revenues by Product Category and Adjustments of Net Revenues for the Impact of Currency and Acquisitions
($ in millions) / (Unaudited)
(a) Includes a reduction in net revenues of $246 million related to the Saudi Arabia customs assessments
Note: Sum of product categories or Regions might not foot to Total PMI due to roundings. “-“ indicates amounts between -$0.5 million and +$0.5 million
Currency
Net
Revenues
excluding
Currency
Acquisitions
Net
Revenues
excluding
Currency &
Acquisitions
Nine Months Ended
September 30,
Net
Revenues 	Total 	Excluding
Currency
Excluding
Currency &
Acquisitions
2021 	Reduced-Risk Products 	2020 	% Change
$ 2,967 	$ 206 	$ 2,761 	$ 2 	$ 2,759 	European Union 	$ 1,861 	59.5% 	48.4% 	48.3%
951 	(45) 	996 	- 	996 	Eastern Europe 	789 	20.5% 	26.2% 	26.2%
98 	1 	97 	- 	97 	Middle East & Africa 	52 	90.2% 	87.7% 	87.7%
7 	- 	7 	- 	7 	South & Southeast Asia 	- 	- 	- 	-
2,659 	36 	2,622 	- 	2,622 	East Asia & Australia 	2,169 	22.6% 	20.9% 	20.9%
42 	1 	41 	- 	41 	Americas 	20 	+100% 	+100% 	+100%
$ 6,724 	$ 200 	$ 6,524 	$ 2 	$ 6,522 	Total RRPs 	$ 4,890 	37.5% 	33.4% 	33.4%
2021 	PMI 	2020 	% Change
$ 9,250 	$ 651 	$ 8,599 	$ 2 	$ 8,597 	European Union 	$ 7,960 	16.2% 	8.0% 	8.0%
2,632 	(74) 	2,706 	- 	2,706 	Eastern Europe 	2,470 	6.6% 	9.6% 	9.6%
2,306 (a)	
(66) 	2,372 	- 	2,372 	Middle East & Africa 	2,348 	(1.8)% 	1.0% 	1.0%
3,284 	102 	3,182 	- 	3,182 	South & Southeast Asia 	3,211 	2.3% 	(0.9)% 	(0.9)%
4,509 	101 	4,408 	- 	4,408 	East Asia & Australia 	4,045 	11.5% 	9.0% 	9.0%
1,320 	38 	1,282 	- 	1,282 	Americas 	1,216 	8.6% 	5.4% 	5.4%
$ 23,301 	$ 752 	$ 22,549 	$ 2 	$ 22,547 	Total PMI 	$ 21,250 	9.7% 	6.1% 	6.1%
Net
Revenues

-- 24 of 27 --

49
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Reconciliation of Net Revenues to Adjusted Net Revenues, excluding Currency and Acquisitions
($ in millions) / (Unaudited)
(a) Represents the Saudi Arabia customs assessments
Net
Revenues
Adjusted
Net
Revenues
Currency
Adjusted
Net
Revenues
excluding
Currency
Acqui-
sitions
Adjusted
Net
Revenues
excluding
Currency
& Acqui-
sitions
Net
Revenues
Adjusted
Net
Revenues
Total 	Excluding
Currency
Excluding
Currency
& Acqui-
sitions
2021 	2020
$ 9,250 	$ - 	$ 9,250 	$ 651 	$ 8,599 	$ 2 	$ 8,597 	European Union 	$ 7,960 	$ - 	$ 7,960 	16.2% 	8.0% 	8.0%
2,632 	- 	2,632 	(74) 	2,706 	- 	2,706 	Eastern Europe 	2,470 	- 	2,470 	6.6% 	9.6% 	9.6%
2,306 	(246) (a)	
2,552 	(66) 	2,618 	- 	2,618 	Middle East & Africa 	2,348 	- 	2,348 	8.7% 	11.5% 	11.5%
3,284 	- 	3,284 	102 	3,182 	- 	3,182 	South & Southeast Asia 	3,211 	- 	3,211 	2.3% 	(0.9)% 	(0.9)%
4,509 	- 	4,509 	101 	4,408 	- 	4,408 	East Asia & Australia 	4,045 	- 	4,045 	11.5% 	9.0% 	9.0%
1,320 	- 	1,320 	38 	1,282 	- 	1,282 	Americas 	1,216 	- 	1,216 	8.6% 	5.4% 	5.4%
$ 23,301 $ (246) 	$ 23,547 	$ 752 	$ 22,795 	$ 2 	$ 22,793 	Total PMI 	$ 21,250 	$ - 	$ 21,250 	10.8% 	7.3% 	7.3%
Special
Items
Special
Items
Nine Months Ended
September 30, 	% Change
50
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Reconciliation of Operating Income to Adjusted Operating Income, excluding Currency and Acquisitions
($ in millions) / (Unaudited)
(a) Represents asset impairment and exit costs
(b) Includes the Saudi Arabia customs assessments ($246 million) and asset impairment and exit costs ($13 million)
(c) Represents asset acquisition cost related to OtiTopic Inc. in August 2021
Operating
Income
Adjusted
Operating
Income
Currency
Adjusted
Operating
Income
excluding
Currency
Acqui-
sitions
Adjusted
Operating
Income
excluding
Currency
& Acqui-
sitions
Operating
Income
Adjusted
Operating
Income
Total 	Excluding
Currency
Excluding
Currency
& Acqui-
sitions
2021 	2020
$ 4,811 	$ (56) (a)	
$ 4,867 	$ 413 	$ 4,454 	$ - 	$ 4,454 	European Union 	$ 3,924 	$ (27) (a)	
$ 3,951 	23.2% 	12.7% 	12.7%
913 	(11) (a)	
924 	(2) 	926 	- 	926 	Eastern Europe 	610 	(7) (a)	
617 	49.8% 	50.1% 	50.1%
739 	(259) (b)	
998 	(74) 	1,072 	- 	1,072 	Middle East & Africa 	819 	(9) (a)	
828 	20.5% 	29.5% 	29.5%
1,208 	(17) (a)	
1,225 	36 	1,189 	- 	1,189 	South & Southeast Asia 	1,290 	(11) (a)	
1,301 	(5.8)% 	(8.6)% 	(8.6)%
2,041 	(67) (a)	
2,108 	(6) 	2,114 	- 	2,114 	East Asia & Australia 	1,792 	(13) (a)	
1,805 	16.8% 	17.1% 	17.1%
367 	(6) (a)	
373 	12 	361 	- 	361 	Americas 	328 	(4) (a)	
332 	12.3% 	8.7% 	8.7%
(51) 	(51) (c)	
- 	- 	- 	- 	- 	Other 	- 	- 	- 	- 	- 	-
$ 10,028 	$ (467) 	$ 10,495 	$ 379 	$ 10,116 	$ - 	$ 10,116 	Total PMI 	$ 8,763 	$ (71) 	$ 8,834 	18.8% 	14.5% 	14.5%
Asset
Impairment
& Exit Costs
and Others
Asset
Impairment
& Exit Costs
Nine Months Ended
September 30, 	% Change

-- 25 of 27 --

51
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Reconciliation of Adjusted Operating Income Margin, excluding Currency and Acquisitions
($ in millions) / (Unaudited)
(a) For the calculation of Adjusted Operating Income and Adjusted Operating Income excluding currency and acquisitions refer to slide 50
(b) For the calculation of Adjusted Net Revenues excluding currency and acquisitions refer to slide 49
Adjusted
Operating
Income
(a)
Adjusted
Net
Revenues
(b)
Adjusted
Operating
Income
Margin
Adjusted
Operating
Income
excluding
Currency
(a)
Adjusted
Net
Revenues
excluding
Currency
(b)
Adjusted
Operating
Income
Margin
excluding
Currency
Adjusted
Operating
Income
excluding
Currency
& Acqui-
sitions (a)
Adjusted
Net
Revenues
excluding
Currency
& Acqui-
sitions (b)
Adjusted
Operating
Income
Margin
excluding
Currency
& Acqui-
sitions
Adjusted
Operating
Income
(a)
Adjusted
Net
Revenues
(b)
Adjusted
Operating
Income
Margin
Adjusted
Operating
Income
Margin
Adjusted
Operating
Income
Margin
excluding
Currency
Adjusted
Operating
Income
Margin
excluding
Currency
& Acqui-
sitions
2021 	2020 	% Points Change
$ 4,867 	$ 9,250 	52.6% 	$ 4,454 	$ 8,599 	51.8% 	$ 4,454 	$ 8,597 	51.8% 	European Union 	$ 3,951 	$ 7,960 	49.6% 	3.0 	2.2 	2.2
924 	2,632 	35.1% 	926 	2,706 	34.2% 	926 	2,706 	34.2% 	Eastern Europe 	617 	2,470 	25.0% 	10.1 	9.2 	9.2
998 	2,552 	39.1% 	1,072 	2,618 	40.9% 	1,072 	2,618 	40.9% 	Middle East & Africa 	828 	2,348 	35.3% 	3.8 	5.6 	5.6
1,225 	3,284 	37.3% 	1,189 	3,182 	37.4% 	1,189 	3,182 	37.4% South & Southeast Asia 	1,301 	3,211 	40.5% 	(3.2) 	(3.1) 	(3.1)
2,108 	4,509 	46.8% 	2,114 	4,408 	48.0% 	2,114 	4,408 	48.0% 	East Asia & Australia 	1,805 	4,045 	44.6% 	2.2 	3.4 	3.4
373 	1,320 	28.3% 	361 	1,282 	28.2% 	361 	1,282 	28.2% 	Americas 	332 	1,216 	27.3% 	1.0 	0.9 	0.9
$ 10,495 $ 23,547 	44.6% 	$ 10,116 $ 22,795 	44.4% 	$ 10,116 $ 22,793 	44.4% 	Total PMI 	$ 8,834 $ 21,250 	41.6% 	3.0 	2.8 	2.8
Nine Months Ended
September 30,
PHILIP MORRIS INTERNATIONAL INC. and Subsidiaries
Reconciliation of Non-GAAP Measures
Net Revenues by Product Category
($ in millions) / (Unaudited)
Note: Sum of Regions might not foot to Total PMI due to roundings. "-" indicates amounts between -$0.5 million and +$0.5 million
Years Ended
December 31,
Reduced-Risk Products 	2020 	2019 	2018 	2017 	2016 	2015
European Union 	$ 2,649 	$ 1,724 	$ 865 	$ 269 	$ 57 	$ 29
Eastern Europe 	1,128 	844 	324 	55 	6 	-
Middle East & Africa 	57 	321 	382 	94 	4 	-
South & Southeast Asia 	1 	- 	- 	- 	- 	-
East Asia & Australia 	2,961 	2,671 	2,506 	3,218 	666 	35
Americas 	31 	27 	19 	4 	1 	-
Total RRPs 	$ 6,827 	$ 5,587 	$ 4,096 	$ 3,640 	$ 733 	$ 64
PMI 	2020 	2019 	2018 	2017 	2016 	2015
European Union 	$ 10,702 	$ 9,817 	$ 9,298 	$ 8,318 	$ 8,162 	$ 8,068
Eastern Europe 	3,378 	3,282 	2,921 	2,711 	2,484 	2,735
Middle East & Africa 	3,088 	4,042 	4,114 	3,988 	4,516 	4,629
South & Southeast Asia 	4,396 	5,094 	4,656 	4,417 	4,396 	4,288
East Asia & Australia 	5,429 	5,364 	5,580 	6,373 	4,285 	3,915
Americas 	1,701 	2,206 	3,056 	2,941 	2,842 	3,159
Total PMI 	$ 28,694 	$ 29,805 	$ 29,625 	$ 28,748 	$ 26,685 	$ 26,794
Net
Revenues
52

-- 26 of 27 --

Delivering a Smoke-Free Future
2021 Third-Quarter Results
October 19, 2021

-- 27 of 27 --